Mackay Shields LLC’s Acadia Pharmaceuticals ACAD Stock Holding History

Mackay Shields LLC’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-21,900	Closed	-$1.06M	–	1413
2020 Q2	$1.06M	Sell	21,900 -41,777	-66%	-$2.01M	0.01%	1000
2020 Q1	$2.69M	Buy	63,677 +500	+0.8%	+$20.6K	0.02%	547
2019 Q4	$2.7M	Sell	63,177 -13,000	-17%	-$566K	0.02%	748
2019 Q3	$2.74M	Sell	76,177 -10,500	-12%	-$318K	0.02%	766
2019 Q2	$2.32M	Buy	86,677 +55,172	+175%	+$1.41M	0.02%	839
2019 Q1	$846K	Sell	31,505 -700	-2%	-$16.3K	0.01%	1048
2018 Q4	$520K	Buy	+32,205	New	+$625K	﹤0.01%	1131

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Mackay Shields LLC's ACAD Position: Q3 2020 in Review

Mackay Shields LLC sold out of Acadia Pharmaceuticals (ACAD) in Q3 2020, closing a stake of 21,900 shares — an estimated $1.06M sold.

Mackay Shields LLC first reported a position in ACAD in Q4 2018 and held it in 7 quarters. The position peaked at $2.74M in Q3 2019. 267 funds tracked by Wall St. Rank hold ACAD as of Q3 2020.

Mackay Shields LLC reported no remaining Acadia Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Mackay Shields LLC sold 21,900 Acadia Pharmaceuticals shares in Q3 2020, an estimated $1.06M.
Mackay Shields LLC first reported a position in Acadia Pharmaceuticals in Q4 2018 and held it in 7 quarters.
Mackay Shields LLC's Acadia Pharmaceuticals position peaked at $2.74M in Q3 2019.
267 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2020.

Based on Mackay Shields LLC's 13F filing for Q3 2020, filed 4 Nov 2020.